These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 39093953)

  • 21. Venetoclax in combination with nucleoside analogs in acute myelogenous leukemia.
    Ball BJ; Koller PB; Pullarkat V
    Curr Opin Oncol; 2022 Sep; 34(5):531-539. PubMed ID: 35855507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of Nrf2-mediated glucose metabolism by brusatol synergistically sensitizes acute myeloid leukemia to Ara-C.
    Cheng C; Yuan F; Chen XP; Zhang W; Zhao XL; Jiang ZP; Zhou HH; Zhou G; Cao S
    Biomed Pharmacother; 2021 Oct; 142():111652. PubMed ID: 34112534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
    Klanova M; Lorkova L; Vit O; Maswabi B; Molinsky J; Pospisilova J; Vockova P; Mavis C; Lateckova L; Kulvait V; Vejmelkova D; Jaksa R; Hernandez F; Trneny M; Vokurka M; Petrak J; Klener P
    Mol Cancer; 2014 Jun; 13():159. PubMed ID: 24972933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death.
    Heo SK; Noh EK; Yu HM; Kim DK; Seo HJ; Lee YJ; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
    BMC Cancer; 2020 Dec; 20(1):1193. PubMed ID: 33276759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The E3 ubiquitin ligase TRAF6 inhibits LPS-induced AKT activation in FLT3-ITD-positive MV4-11 AML cells.
    Schnetzke U; Fischer M; Kuhn AK; Spies-Weisshart B; Zirm E; Hochhaus A; Müller JP; Scholl S
    J Cancer Res Clin Oncol; 2013 Apr; 139(4):605-15. PubMed ID: 23263202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia.
    Degwert N; Latuske E; Vohwinkel G; Stamm H; Klokow M; Bokemeyer C; Fiedler W; Wellbrock J
    Eur J Haematol; 2016 Sep; 97(3):239-44. PubMed ID: 26613208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
    Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
    Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iron Oxide Nanoparticles Combined with Cytosine Arabinoside Show Anti-Leukemia Stem Cell Effects on Acute Myeloid Leukemia by Regulating Reactive Oxygen Species.
    Dou J; Li L; Guo M; Mei F; Zheng D; Xu H; Xue R; Bao X; Zhao F; Zhang Y
    Int J Nanomedicine; 2021; 16():1231-1244. PubMed ID: 33633448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Assi R; Kantarjian HM; Kadia TM; Pemmaraju N; Jabbour E; Jain N; Daver N; Estrov Z; Uehara T; Owa T; Cortes JE; Borthakur G
    Cancer; 2018 Jul; 124(13):2758-2765. PubMed ID: 29660836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.
    Hu S; Niu H; Inaba H; Orwick S; Rose C; Panetta JC; Yang S; Pounds S; Fan Y; Calabrese C; Rehg JE; Campana D; Rubnitz JE; Baker SD
    J Natl Cancer Inst; 2011 Jun; 103(11):893-905. PubMed ID: 21487100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting a mitochondrial E3 ubiquitin ligase complex to overcome AML cell-intrinsic Venetoclax resistance.
    Nakao F; Setoguchi K; Semba Y; Yamauchi T; Nogami J; Sasaki K; Imanaga H; Terasaki T; Miyazaki M; Hirabayashi S; Miyawaki K; Kikushige Y; Masuda T; Akashi K; Maeda T
    Leukemia; 2023 May; 37(5):1028-1038. PubMed ID: 36973350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
    Yamauchi T; Negoro E; Kishi S; Takagi K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
    Biochem Pharmacol; 2009 Jun; 77(12):1780-6. PubMed ID: 19428333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long noncoding RNA DANCR confers cytarabine resistance in acute myeloid leukemia by activating autophagy via the miR-874-3P/ATG16L1 axis.
    Zhang H; Liu L; Chen L; Liu H; Ren S; Tao Y
    Mol Oncol; 2021 Apr; 15(4):1203-1216. PubMed ID: 33638615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression.
    Juul-Dam KL; Shukla NN; Cooper TM; Cuglievan B; Heidenreich O; Kolb EA; Rasouli M; Hasle H; Zwaan CM
    Eur J Med Genet; 2023 Dec; 66(12):104869. PubMed ID: 38174649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SAMHD1 protects cancer cells from various nucleoside-based antimetabolites.
    Herold N; Rudd SG; Sanjiv K; Kutzner J; Bladh J; Paulin CBJ; Helleday T; Henter JI; Schaller T
    Cell Cycle; 2017 Jun; 16(11):1029-1038. PubMed ID: 28436707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The m6A modulator-mediated cytarabine sensitivity and immune cell infiltration signature in acute myeloid leukemia.
    Yang J; Li L; Cheng J; Lu J; Zhang S; Wang S; Zhao L; Zhou L
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11457-11469. PubMed ID: 37391640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy.
    Cartel M; Mouchel PL; Gotanègre M; David L; Bertoli S; Mansat-De Mas V; Besson A; Sarry JE; Manenti S; Didier C
    Leukemia; 2021 Feb; 35(2):417-432. PubMed ID: 32447346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
    Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
    J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination strategies to promote sensitivity to cytarabine-induced replication stress in acute myeloid leukemia with and without DNMT3A mutations.
    Shabashvili DE; Feng Y; Kaur P; Venugopal K; Guryanova OA
    Exp Hematol; 2022 Jun; 110():20-27. PubMed ID: 35306047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progressive Purkinje cell degeneration in tambaleante mutant mice is a consequence of a missense mutation in HERC1 E3 ubiquitin ligase.
    Mashimo T; Hadjebi O; Amair-Pinedo F; Tsurumi T; Langa F; Serikawa T; Sotelo C; Guénet JL; Rosa JL
    PLoS Genet; 2009 Dec; 5(12):e1000784. PubMed ID: 20041218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.